non-small cell lung cancer (NSCLC)
Conditions
Interventions
case series:None
Sponsors
Shanghai Chest Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Histologically or cytologically confirmed inoperable advanced (IIIB or IV) NSCLC patients; 2. Tissue samples confirmed the presence of EGFR sensitive mutations; 3. Receiving first-line EGFR-TKI targeted therapy; 4. Aged >= 18 years; 5. The test results of the patient within 2 weeks before receiving EGFR-TKI treatment meet the following criteria: (1) Neutrophil count > 1,500/mcL Heathco-Pioneer Cancer Research Fund; (2) Platelets > 50,000/mcL; (3) Total bilirubin 1+, the 24-hour total urine protein must be < 500 mg; (7) The coagulation function test results are within the normal range; 6. Understand and voluntarily sign the written informed consent; 7. The investigator judged that the patient had good compliance.
Exclusion criteria
Exclusion criteria: 1. There are uncontrollable concurrent diseases, including but not limited to: symptomatic congestive heart failure, unstable angina pectoris and myocardial infarction, uncontrolled grade III hypertension, liver insufficiency, renal insufficiency, uncontrolled diabetes and blood sugar, arrhythmia, mental illness or social conditions, etc.; 2. Patients who are pregnant or breastfeeding; 3. Participate in any other drug research test; 4. HIV-positive patients who are receiving combined antiretroviral combination therapy; 5. The patient has received any malignant tumor surgery (including but not limited to lung cancer); 6. Disease progression within 1 month of treatment or other conditions that consider primary drug resistance; 7. Disease progression judged by discontinuation of drug due to adverse reactions during treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Circulating Tumor Cells;Gene Sequencing; | — |
Countries
China
Contacts
Public ContactJiang Liyan
Shanghai Chest Hospital
Outcome results
None listed